Eli Lilly announced on " Good Morning America " Monday that its GLP-1 weight-loss drug Zepbound will now be available in a new multi-dose KwikPen, giving patients a simpler way to receive a full month of treatment in one device.

Eli Lilly, the drugmaker behind weight-loss treatments Mounjaro and Zepbound, has rapidly overtaken former market leader Novo Nordisk in the obesity drug race. While Novo’s shares have struggled this year, Lilly has projected roughly 25 percent growth, underscoring just how dramatically the balance of power has shifted in the booming GLP-1 market.

Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss drugs.

Add Yahoo as a preferred source to see more of our stories on Google. There are currently thought to be about 1.6 million people on weight-loss drugs in the UK. Some people are able to get the injections - the most popular are called Mounjaro and Wegovy ...

The drugmaker unveiled a new Zepbound delivery system as its main rival absorbed fresh clinical and stock-market blows.

Australian researchers warn GLP-1 weight-loss drugs may cause scurvy, the historic "pirate disease," due to poor nutrition and vitamin C deficiency risks.